Nintedanib and Sarilumab

The combination of nintedanib and sarilumab represents a therapeutic approach that has been documented in medical literature for treating rheumatoid arthritis (RA) complicated by interstitial lung disease (ILD). Nintedanib is an antifibrotic agent and a triple angiokinase inhibitor that blocks multiple tyrosine kinases involved in fibrogenesis. Sarilumab is a fully human monoclonal antibody that binds to interleukin-6 (IL-6) receptors, thereby inhibiting IL-6 signaling. This combination therapy is designed to address both the inflammatory component of RA and the fibrotic lung manifestations of ILD. As of the provided information, this specific combination is not a standard approved therapy with extensive clinical trial data but has been reported in at least one case study.